August 2022 - Volume 81 - 8

REVIEW

1. Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go? 

RECOMMENDATION

2. 2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases 

THINKING THE UNTHINKABLE

3. Learning from chess engines: how reinforcement learning could redefine clinical decision-making in rheumatology 

RHEUMATOID ARTHRITIS

4. Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study 

5. Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset 

6. Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis 

7. Deletion of activin A in mesenchymal but not myeloid cells ameliorates disease severity in experimental arthritis 

8. Epithelial HIF2α expression induces intestinal barrier dysfunction and exacerbation of arthritis 

PSORIATIC ARTHRITIS

9. Concise report: a minimal-invasive method to retrieve and identify entheseal tissue from psoriatic arthritis patients 

SYSTEMIC LUPUS ERYTHEMATOSUS

10. Biological impact of iberdomide in patients with active systemic lupus erythematosus 

11. Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort 

12. Auxilin is a novel susceptibility gene for congenital heart block which directly impacts fetal heart function 

VASCULITIS

13. CSF2-dependent monocyte education in the pathogenesis of ANCA-induced glomerulonephritis 

AUTOINFLAMMATORY DISORDERS

14. Low-ratio somatic NLRC4 mutation causes late-onset autoinflammatory disease

OSTEOARTHRITIS

15. Krüppel-like factor-4 and Krüppel-like factor-2 are important regulators of joint tissue cells and protect against tissue destruction and inflammation in osteoarthritis 

EPIDEMIOLOGY

16. Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination 

LETTERS

17. Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 vaccine in patients with systemic lupus erythematosus (SLE) 

18. Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years 

19. No excess mortality in contemporary undifferentiated arthritis, in contrast to rheumatoid arthritis: a study with a follow-up of at least 10 years 

20. Comparison of ultrasound attenuation by calcium pyrophosphate, hydroxyapatite and monosodium urate crystals: a proof-of-concept study 

21. Eosinopenia to differentiate crystal-induced and septic arthritis 

ELECTRONIC PAGES

22. COVID-19 in patients with rheumatic diseases: what is the real mortality risk? 

23. Response to: ‘COVID-19 in patients with rheumatic diseases: what is the real mortality risk?’ by Marques et al 

24. Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’ 

25. Response to: ‘Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’’ by Pethoe-Schramm et al 

26. Comment on: ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Gossec et al 

27. Response to: ‘Comment on: ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Gossec et al’ by Wei et al 

28. Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial—comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al 

29. Response to: ‘Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial–comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al’ by Bettiol et al 

30. Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa? 

31. Response to: ‘Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?’ by Akpabio et al 

32. Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic 

33. Response to ‘Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic’ by Chuah et al 

34. Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in rheumatism patients in Wuhan, China’

35. Response to: ‘Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in patients with rheumatism in Wuhan, China’’ by Chen et al 

36. Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia 

37. Response to: ‘Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia’ by Wan et al 

38. Should patients starting biologics be screened for COVID-19? 

39. Response to: ‘Should patients starting biologics be screened for COVID-19?’ by Cardenas-de la Garza et al 

40. Implications of SARS-CoV-2 infection for patients with rheumatic disease 

41. Response to: ‘Implications of SARS-CoV-2 infection for patients with rheumatic disease’ by Lin et al 

42. Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest? 

43. Response to: ‘Emergency arising from patients’ fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?’ by Santos-Moreno et al 

44. Correction: B cell subset composition segments clinically and serologically distinct groups in chronic cutaneous lupus erythematosus

ISSUE INFORMATION